Protokoly_diagnostiki_i_lechenia_zabolevany
.pdf: " .
@ :
1." .
2.) " .
3.".
& " 2 " 10 . &
|
|
" |
" |
21 |
||
, % " . |
? & " |
& |
||||
|
&$ " 2 &. |
|
||||
" $ " 8-12 |
# . |
|
|
|||
& , " |
|
& |
||||
|
|
" & & |
- & % [3]. % & 3[3]:
1.% % 1 ., " .
2.% % 1
% % % # " & # .
3. |
J$ , |
% % |
|||||
% # " . |
|
||||||
1-2 |
|
( |
|||||
% |
& |
|
), |
|
% & |
||
. @ |
3 & "$ , |
||||||
$# & . |
|
||||||
! [3]: |
|
|
|
|
|||
1. |
1-2 |
– |
3-4 |
\ 1,0-2,0; |
|||
2. |
3 |
– |
3-4 |
\ 1,0-2,0 " 12 " |
(2 ) 7 + 100 . / " 8 " (3 ) 3-5 .
" & :
1.*6 250 0,5 100
2.*/ V 250 , 500 , 1000
3.*/ V 1000
" & & :
,- ! :
|
& " ; |
|
) % " % ; |
% " .
/ , & :
1." , & : . . / . M.J. K " , B.+. @ , '.B. , .6. G . — 2- ., . — 6.: 7 ;?-6>@, 2002. — 1248 .: .
2.Blow-out fractures. EBM Guidelines.25.06.2001 Author: Antti Pihakari. Article ID: ebm00372 (018.104)© 2005 Duodecim Medical Publications Ltd
3.Work Loss Data Institute. Forearm, wrist, and hand. Corpus Christi (TX): Work Loss Data Institute; 2004. 67 p.
* – , # (% % )
"
: 03-030
"$ &: " :
& ! : "$, , , .
' & & : 11
(: S02 " B$" : :
-(S02.1)
-(S02.3)
: + & . ! " - % "
%$# . |
|
|
|
|
|
|
|
|
|
|
|
||||||
: "$, , |
% |
||||||||||||||||
"$, % " |
|
|
|
|
|
||||||||||||
_ : &, % % , " |
|
||||||||||||||||
" |
: 3 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
: |
|
|
|
|
|
|
|
|
|
|
|
|
|
?) |
% "$: |
|
|
|
|
|
|
|
|
|
|
|
|||||
1. |
! " - + " |
% "$ ( " |
|||||||||||||||
). |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
2. |
- |
& % "$. " |
$ |
|
[ |
||||||||||||
|
& & [ . + % & |
& . + " |
|||||||||||||||
|
|
|
|
" |
& |
|
. ! & |
||||||||||
" |
% "$. ! & . |
||||||||||||||||
«! & » - |
|
. + & |
. |
||||||||||||||
" & " |
. $ " & & |
||||||||||||||||
% "$. >[ |
|
$ |
|
# |
|
||||||||||||
%$ & . |
|
|
|
|
|
|
|
|
|
|
|
||||||
3. |
% "$ " & |
||||||||||||||||
" |
% |
|
, |
|
|
|
|||||||||||
" . |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<) & |
" |
: |
|
|
|
|
|
|
|
|
|||||||
1. |
: |
+ |
& |
|
|
% |
|
|
" V[ % % "$. " & , # , "" . + &, " . B. " %$ $#$ ( [ ) .
') J : %$ [ ,[ , " ( " & " ). < & "$.
- J III: " , %$ "$ % & . ' % " &"$. + & % " . , $# & " & ,& , $ % .
" & :
1. "
2."
3." & &
4.# (6 )
5.# "
6.B
7.6
9.
10.& "
11.7
12._ $
13.HbsAg, Anti-HCV.
" & & :
1.&$ "
4.$
+ |
: |
|
|
|
|
|
?) " |
% "$: |
|
||||
- " ( " |
, % ) |
|||||
& |
, & " & % |
|||||
. |
|
|
|
|
|
|
• ' " $ |
|
# $" "$&. |
||||
• ! |
& " " $. ' 3 |
" & |
||||
. |
|
|
|
|
|
|
- + " & & |
% |
"$ $ & |
||||
" . > |
# [ & |
|||||
, |
& : – |
|||||
"$ " . |
||||||
• " & & 4-5 . |
||||||
• 6 % & |
[ , &$ |
|||||
& . _ |
" |
|||||
" & , |
3 [ & %"$ |
|||||
4-5 . |
|
|
|
|
|
|
" " . % :
-6% " % "$ % % " & % .
-' % [ % " , $# "$.
-@ " &" ( [ % % " 6 ).
<) 6 & % : #&$
$" J . > $ & % % & [ ,[ &$ , % , &$ .
') J . J III:
$ " % "$. + & & . L &$ , &$ , , .
% :
- B " " # & " & . B "$& [ #[ , " &$$ .
) , $# :
" " ( , ). + % , % " 3 .
> " , & |
" &$, % |
|||
" & % . |
|
|||
6 : |
|
|
|
|
- + %$$ |
% |
& |
"$ |
|
#&$ |
. ' |
# |
$ |
|
|
. %$$ |
$ #&$ " , #.
' " & % % & " 6 . H" ( , $").
% :
- ' V[ % & 3 & , % %. ! " &$ " & .
" & :
1.*6 250 0,5 100
2.*/ V 250 , 500 , 1000
3. */ V 750
4.*7 70% ( )
5.*@ V 1% 1
6.* 0,25
7.*_ 1:5000
8.*7 V 0,18% 1
" & & :
,- ! : , .
/ , & :
1.Fractures of the mandible.EBM Guidelines.29.09.2001. Author: Antti Pihakari. Article ID: ebm00369 (018.013). © 2005 Duodecim Medical Publications Ltd.
2.Facial injuries. .EBM Guidelines.29.09.2001. Author: Antti Pihakari. Article ID: ebm00390 (018.019). © 2005 Duodecim Medical Publications Ltd.
3." , & : . . / . M.J. K " , B.+. @ , '.B. , .6. G . — 2- ., . — 6.: 7 ;?-6>@, 2002. — 1248 .: .
* – , # (% % ) .
8
: 09-126
"$ &: " :
& !: "
' & & ( ): 15
(: C50 ) " " %
) : 8 – 3 " " % .$ : ' # & & "$ $
6 % |
$, |
TNM |
% |
$ (2002 .). ! " |
& , " (pTNM). & % , % " % .
' " " "-% " % ,% & & ;. !" % , % &
, " & % & " " |
. |
* : , |
% |
, " " % , " 6D,& , & ( , & ), " " , # % ,
" , |
, % , |
& |
|
" % , " / , " % . |
|||
" |
: |
|
|
" |
: " & , " |
||
% |
" " " |
% |
|
" . J " |
|||
& . |
|
|
5 : "
" , ? (6 |
), ?6, & /$ (9 |
|||||
), & , 7 , _ R- , H)B " % , |
||||||
, " , , . @ , 6 ;, ; " |
||||||
% , |
(7 -, 7 +, Her-2-neu), |
, !?15-3 % |
||||
|
. |
|
|
|
||
|
: V - " " % , & |
|||||
|
" & &, |
( |
), & |
|||
|
( |
); V |
– " % , |
|||
, |
, |
|
% |
, % |
« & », |
% " % , , |
|||||
& " % , |
" / . @ & |
|||||
& |
, |
, |
|
" |
% , |
|
|
, , . |
|
|
" & :
2."
3." 3 _
4.! 7
6."
7.# "
8.#
9./ " "
11."
12.B 'BL
13.6
14. |
HbsAg, Anti-HCV. |
17.1 ( , , , " , " & , )
18."
19.$
20.?J;
21.?!;
22.;
23. -
24.H)B $
25.7
27.H)B " %
28.6
29.@
30.H)B
31.6 ; " %
32.; " %
" & & :
1. &
+ . 6D "$ " &
, , & $" |
|
, & |
|
% / % , " " & . ". @ ( % , " H)B) . ; & (;?<) – "" % " H)B ( ).- " . ; -& " " &$" " . G " ;?< - &/$" & " . &$ - $& " , $" " % " , , .
V & V % . ; % % &" . @ "
|
& 400 \ " |
7 . |
|
|
$# , & 3 . |
$# ( 3 : " &% ; & " % ;" % : " &% ; 3 : " %
|
" , |
||
2 ) |
4 " |
|
|
" . & 3 6 |
( |
" |
|
% & , " ) |
|
4 , % " , & " % , % % " $# . ' "( 40 ) " &$# , %& " , 10-15" & 40 . <) " % " " & . $#6D "$, % , " & & . ! &- && " % , " 3 .
$ $# " % : ) – $, $" &$; ) " 2,5 ;
) % 3 ;
) & " ( , H)B " );
) , " 3( );
) " % "" & ;
%) ; ) " " " ;
) % & & "$ % .
6D – " , " .
" & :
1. *; V 1% 1
2.*š + + +' 25
3.400
4.*@ 200 , 400 ,
5.100 % ; 10 /5 .
6.*? 50 , 100 , 500 .; 5%, 10% 2 , 5 .
7.*$ 5% 400
8.*+ & " " &
9.*B & 150 – 10 \
" & & :
1. *? & 5%, 10%, 20% ;
3. * V & 5 000, 25 000 6>;
2. *B " " , " V 100 6>/,- ! : , & ( )
/ , & :
1.Breast cancer treatment. Institute for Clinical Systems Improvement (ICSI). Breast cancer treatment. Bloomington (VN): Institute for Clinical Systems Improvement (ICSI); 2004 Sep. 41 p. [77 references]
2.Adjuvant Systemik Therapy for Node-negative Breast Cancer. Practic Guideline Report #1-8. Most Recent Literature search: May 1, 2003
3.The role of the Taxanes in the Management of Metastatic Breast cancer. Practic Guideline Report #1-3. April 24, 2004
4.Capecetabine in Stage IY Breast Cancer. Practic Guideline Report #1-16. Version 2, 2003
5.The Role of Aromatase Inhibitors in the Treatment of Postmenopausal Women with Metastatic Breast cancer. Practic Guideline Report #1-11. (Version 2.2002)
6.Practic Guideline Report #1-5. Recommendations modified: October 2003
7.@ & . >% " . 2003, .2, " &5.
* – , # (% % )
: 21-175 |
|
|
|||
|
|
||||
"$ &: " |
|
|
|||
: |
|
|
|
||
& |
! : |
" , |
|||
|
" |
|
( , ), |
% |
|
% . |
|
|
|
||
' |
& & ( ): 12 |
|
|||
(: |
|
|
|
||
T01 , $# & |
|
||||
S21 |
|
|
|||
S31 |
% , % " |
|
|||
S41 |
|
" |
" |
|
|
S51 |
|
"& |
|
|
|
S61 |
& |
|
|||
S71 |
|
|
|||
S81 |
|
|
|
||
S91 |
|
|
|||
S16 |
; % |
|
|||
S19 |
@ " |
|
S19.7 |
6 % |
S19.8 |
@ " |
S19.9 |
; " |
T01.0
T01.1 , % , % " T01.2 & ( ) "
T01.3 & % ( ) "
T01.6 & ( ) % " T01.8 @ " , $# & T01.9 6 % "
) : – % " ,%$# % " [1].
$ : [1,2].
1. |
– & ; |
2. |
– & , 0,5 .; |
3. |
H – & & ; |
4.H – & % , % , " ;
5.! & – % % " % # ;
6.& – & & % .
* : # .
" |
: 3 |
|
: |
< " ;
|
' % % " ; |
|
|
" |
% " ; |
|
B " ( , , .); |
|
|
& |
" ; |
|
! $# " ( " & , |
.); |
|
|
% % ; |
" % # .
" & :
1. ;
2.( V % );
3." ( . );
4. " 2- .
5.# ;
6.# " ;
7.;
8.< ;
9.'BL, HbsAg, Anti-HCV.
" & & :
+
+ & .
! " % & "[2].
" :
1." " ;
2.." :
1. |
+ % " |
; |
2. |
? |
" 3-5 , " |
8 " :
% % ;
, $# ;
;
B ;
|
% ; |
|
H . |
3. |
" % % |
|
" . |
|
|
|
& |
|
, |
" |
& |
|
& |
- |
||
& % . % & 3 |
: |
1.; % % 1 ., " .
2.; % % 1 % % % # " & # .
3.J$ % % % # ".
1-2 ( % & ), - % & . @
|
3 & "$ , $# -& |
. |
|
! : |
|
|
1-2 – 500 . " 6 " 5-10 per os; |